WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016083820) N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS,
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/083820    International Application No.:    PCT/GB2015/053615
Publication Date: 02.06.2016 International Filing Date: 26.11.2015
Chapter 2 Demand Filed:    15.09.2016    
IPC:
C07D 401/14 (2006.01), C07D 413/14 (2006.01), A61K 31/415 (2006.01), A61K 31/454 (2006.01), A61K 31/4709 (2006.01), A61K 31/497 (2006.01), A61K 31/506 (2006.01), C07D 231/14 (2006.01), C07D 401/06 (2006.01), C07D 401/10 (2006.01), C07D 403/10 (2006.01), C07D 409/14 (2006.01)
Applicants: KALVISTA PHARMACEUTICALS LIMITED [GB/GB]; Building 227 Tetricus Science Park Porton Down Salisbury SP4 0JQ (GB)
Inventors: DAVIE, Rebecca Louise; (GB).
EDWARDS, Hannah Joy; (GB).
EVANS, David Michael; (GB).
HODGSON, Simon Teanby; (GB)
Agent: PHILLIPS, Gillian Margaret; (GB)
Priority Data:
1421083.5 27.11.2014 GB
Title (EN) N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS,
(FR) COMPOSÉS N-((HET)ARYLMÉTHYL)-HÉTÉROARYL-CARBOXAMIDES COMME INHIBITEURS DE LA KALLIKRÉINE PLASMATIQUE
Abstract: front page image
(EN)The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
(FR)La présente invention concerne des composés de formule (I), des compositions comprenant lesdits composés ; l'utilisation desdits composés en thérapie (par exemple dans le traitement ou la prévention d'une maladie ou d'un état avec implication de l'activité de la kallikréine plasmatique) ; et des méthodes de traitement de patients par lesdits composés ; R5, R6, R7, A, B, W, X, Y et Z étant tels que définis dans la description.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)